Can AI predict treatment response in patients with prostate cancer?
Thursday, November 30 | 1:40 p.m.-1:50 p.m. | R6-SSNMMI08-2 | Room S403AAn AI model based on F-18 DCFPyL PSMA-PET/CT images will be presented here that shows promise for predicting treatment response in patients with metastatic castration-resistant prostate cancer (mCRPC).Despite the widespread adoption of prostate-specific membrane antigen (PSMA)-PET/CT imaging for prostate cancer, prognostication of patient outcomes remains challenging. The goal of this work was to evaluate the feasibility of a deep-learning model to identify patients at risk for progression based on baseline PSMA-PET, noted Andrew Voter, MD, of Johns H...
Source: AuntMinnie.com Headlines - November 15, 2023 Category: Radiology Authors: Will Morton Tags: 2023 Molecular Imaging Preview Source Type: news
Ga-68 RM2-PET effective in prostate cancer relapse cases
Sunday, November 26 | 9:20 a.m.-9:30 a.m. | S1-SSNMMI01-3 | Room E350Gallium-68 (Ga-68) RM2-PET imaging should be considered in patients with biochemical recurrent (BCR) prostate cancer to aid in disease detection and management decisions, according to a study to be presented in this session.National Comprehensive Cancer Network guidelines include prostate-specific membrane antigen (PSMA) PET for the detection of BCR, yet up to 10% of cases do not express PSMA, noted presenter Heying Duan, MD, a nuclear medicine research scientist at Stanford University.Duan and colleagues developed a tracer called Ga-68 RM2, which targets...
Source: AuntMinnie.com Headlines - November 15, 2023 Category: Radiology Authors: Will Morton Tags: 2023 Molecular Imaging Preview Source Type: news
Practice-Changing Data in Prostate Cancer From ESMO 2023 Practice-Changing Data in Prostate Cancer From ESMO 2023
Survival benefits using radioligand therapy and analyses identifying novel ways to better target treatment are among the prostate cancer highlights from ESMO 2023 discussed by Dr Oliver Sartor.Medscape (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - November 13, 2023 Category: Radiology Tags: Hematology-Oncology ReCAP Source Type: news
Man, 64, wouldn't have known he had stage 2 prostate cancer if it wasn't for one thing
David McMurray was still hurling stones around the garden, chasing his kids' two dogs around, and going about normal life when he was diagnosed with stage 2 prostate cancer (Source: Daily Express - Health)
Source: Daily Express - Health - November 11, 2023 Category: Consumer Health News Source Type: news
187 New Genetic Variants Linked to Prostate Cancer Found
International collaboration explored genomes of nearly 950,000 men, finding a total of 451 variants and refining what is known about genetic risk for prostate cancer (Source: Disabled World)
Source: Disabled World - November 9, 2023 Category: Disability Tags: Prostate Cancer Source Type: news
Road to RSNA 2023: AI Preview
Welcome to the first installment of this year’s Road to RSNA preview of the RSNA 2023 meeting. We’re once again providing a modality-by-modality overview of select scientific presentations to serve as your guide to events at McCormick Place.
Our journey along the Road to RSNA begins again with our preview of AI, a topic that has dominated the annual meeting for the past seven years. Research on AI topics will be omnipresent, featuring both in dedicated sessions as well as throughout the scientific program. In fact, it’s hard to find a scientific session without at least one AI-related presentation.
AI’s capabilit...
Source: AuntMinnie.com Headlines - November 8, 2023 Category: Radiology Authors: Erik L. Ridley Tags: 2023 Source Type: news
Active Surveillance for Prostate Cancer a Leap of Faith
Should men with low-grade prostate cancer skip treatment and opt for active surveillance? That’s the question thousands of aging men must consider as the likelihood they will die from a low-grade prostate cancer diagnosis appears low. (Source: WebMD Health)
Source: WebMD Health - November 7, 2023 Category: Consumer Health News Source Type: news
A conserved mechanism for JNK-mediated loss of Notch function in advanced prostate cancer | Science Signaling
Analysis of Notch signaling suggests a tumor-suppressive role for Notch in Drosophila tumors and in advanced prostate cancer. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - November 7, 2023 Category: Science Source Type: news
Black Men More Likely Than Whites to Have Prostate Cancer at Any Given PSA Level
MONDAY, Nov. 6, 2023 -- At any given prostate-specific antigen (PSA) level, Black men are more likely than White men to develop prostate cancer, according to a study published online Nov. 6 in Cancer.Kyung Min Lee, Ph.D., from the VA Salt Lake City... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 6, 2023 Category: Pharmaceuticals Source Type: news
Younger-Aged Black Men Have Higher Prostate Cancer Risk Younger-Aged Black Men Have Higher Prostate Cancer Risk
Black men are at higher risk of prostate cancer than their White counterparts at younger ages and lower prostate-specific antigen (PSA) levels.MDedge News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 6, 2023 Category: Consumer Health News Tags: Urology News Source Type: news
At Same PSA Levels, Black Men Still More Likely to Get Prostate Cancer Than Whites
MONDAY, Nov. 6, 2023 -- Even with the same prostate-specific antigen (PSA) levels, Black men are more likely to have prostate cancer than white men, new research shows.
The findings point to the need for earlier and more frequent screening, the... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 6, 2023 Category: General Medicine Source Type: news
Reduced-Dose Schedule of Cabazitaxel Viable for Seniors With mCRPC
(MedPage Today) -- A reduced-dose schedule of cabazitaxel (Jevtana) plus prophylactic granulocyte colony-stimulating factor (G-CSF) should be offered to older men with metastatic castration-resistant prostate cancer (mCRPC), according to results... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 1, 2023 Category: Hematology Source Type: news
AMA issues new CPT code for AI prostate cancer mapping
Avenda Health highlighted a new American Medical Association (AMA) category III 2024 Current Procedural Terminology (CPT) code for prostate cancer mapping.The new code (X237T) covers “AI Generated Prostate Cancer Mapping,” described by the AMA as follows:“Noninvasive prostate cancer estimation map, derived from augmentative analysis of image-guided fusion biopsy and pathology, including visualization of margin volume and location, with margin determination and physician interpretation and report.”Category III designations are temporary codes for new and developing technologies, such as Avenda’s Unfold AI software...
Source: AuntMinnie.com Headlines - November 1, 2023 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news
Docetaxel Use Associated With Significant Reduction in Prostate Cancer Death in Very Poor Prognostic Group
A meta-analysis of five prospective randomized clinical trials (RCTs) found that adding docetaxel to standard-of-care (SOC) treatment was associated with a 70% reduction in death from prostate cancer-specific mortality (PCSM). (Source: BWH News)
Source: BWH News - November 1, 2023 Category: Hospital Management Source Type: news
ESMO 2023: Advancing Prostate Cancer Care ESMO 2023: Advancing Prostate Cancer Care
Dr Rana R. McKay offered insights on the practice-changing data presented at ESMO 2023.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 27, 2023 Category: Consumer Health News Tags: None MDAngle Source Type: news
